Expands ICON's leadership in Health Outcomes Research and
Commercialisation Services
DUBLIN--(BUSINESS WIRE)--
ICON plc, (NASDAQ:ICLR) a global provider of drug development
solutions and services to the pharmaceutical, biotechnology and medical
device industries, today announced that it has acquired the Mapi Group,
a leading Patient-Centered Health Outcomes Research and
Commercialisation company.
The acquisition strengthens ICON's existing Commercialisation and
Outcomes Research business adding significant commercialisation
presence, analytics, real world evidence generation and strategic
regulatory expertise. The combined organisation will be a leader for
real world evidence, post approval research, language services,
consultancy services supporting clinical outcomes assessments, pricing
and market access and scientific communications.
The acquisition also enables ICON to have direct access to Mapi
Research Trust, the industry's most subscribed library of Clinical
Outcomes Assessments (COAs), with exclusive distribution of over 300
families of validated questionnaires, including licensing of COA
services used by commercial, academic and regulatory research
organisations.
"The late phase CRO market continues to grow as our customers
face greater scrutiny from regulators and reimbursement bodies around
real-world evidence of product value and safety," commented Dr.
Steve Cutler, Chief Executive Officer, ICON plc. "The acquisition of
Mapi extends the breadth and depth of ICON's late phase capabilities,
creating an industry leading provider of post-approval research,
spanning evidence generation, strategic regulatory services, scientific
communications and commercial strategy. Our customers will also benefit
from ICON's access to the industry's broadest set of COA tools and
instruments as well as new and enhanced real world data sets. Mapi has
been a pioneer of late phase and outcomes research since their
foundation and we are delighted to welcome their team of experts to
ICON."
"By combining with ICON, our customers will have access to a broader
global footprint, additional depth of experience, new scientific
communication services and access to innovative solutions to capture
real world data from patients," commented James Karis, CEO of
Mapi Group. "In addition, our customers will have access to a wide
range of global clinical services, spanning all phases of development.
Mapi and ICON are an ideal combination, having complimentary services
and a shared mission to provide superior research solutions that help
improve the lives of patients globally."
"I am delighted that Mapi will become part of ICON, a company that
has a similar culture and vision that will enable Mapi to continue the
focus on innovation that we have developed over the last forty-three
years," commented Bernard Jambon, Mapi's founder and Chairman of the
Board of Directors.
About Mapi Group
Mapi Group has over 40 years of experience supporting Life-Science
companies as the world leading Patient-Centered Research company in
commercializing novel treatments through Real-World Evidence, Strategic
Regulatory Services, Pharmacovigilance, Market Access, Language
Services. Mapi Group is the premier provider of Health Research and
Commercialization services to Life-Science companies enabling Market
Authorization, Market Access and Market Adoption of novel therapeutics.
Visit http://www.mapigroup.com
for more information.
About ICON plc
ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 84 locations in 38 countries and
has approximately 12,300 employees.
Further information is available at www.iconplc.com
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at http://www.sec.gov.
ICON/ICLR-F
View source version on businesswire.com: http://www.businesswire.com/news/home/20170727005556/en/
Investor Relations, 1-888-381-7923
or
Brendan Brennan, + 353 1
291 2000
Chief Financial Officer
or
Jonathan Curtain,
+1-215-616-3000
Vice President Corporate Finance & Investor
Relations
Source: ICON plc
News Provided by Acquire Media
